Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 169-177

  Cherukuri, Durga P ^a   Ishikawa, Tomo o ^a   Chun, Patrick ^a   Catapang, Art ^a   Elashoff, David ^a   Grogan, Tristan R ^a   Bugni, James ^a   Herschman, Harvey R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

APC; COX2; Cyclooxygenase 2; Gender specific effect; Mouse intestinal tumors

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 2;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GENE TARGETING; INTESTINE EPITHELIUM CELL; INTESTINE POLYP; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; ADENOMATOUS POLYPOSIS COLI GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CYCLOOXYGENASE 2 GENE; GENE; INTESTINE TUMOR;

MUS;

APC; COX2; CYCLOOXYGENASE 2; GENDER-SPECIFIC EFFECT; MOUSE INTESTINAL TUMORS;

ADENOMATOUS POLYPOSIS COLI; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CYCLOOXYGENASE 2; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; INTESTINAL MUCOSA; MALE; MICE; MICE, KNOCKOUT; SEX CHARACTERISTICS;

EID: 84894296700     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.009     Document Type: Article

References (28)

1. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L., Katkuri S., DuBois R.N. 15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 2005, 280:3217-3223.
2. Brosens L.A., Keller J.J., Pohjola L., Haglund C., Morsink F.H., Lacobuzio-Donahue C., Goggins M., Giardiello F.M., Ristimaki A., Offerhaus G.J. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol. Ther. 2008, 7:424-427.
3. Chillingworth N.L., Morham S.G., Donaldson L.F. Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R327-R334.
4. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000, 60:4705-4708.
5. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase-2 expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
6. Egan K.M., Lawson J.A., Fries S., Koller B., Rader D.J., Smyth E.M., Fitzgerald G.A. COX2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
7. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328:1313-1316.
8. Gupta R.A., DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. 2001, 1:11-21.
9. Higuchi T., Iwama T., Yoshinaga K., Toyooka M., Taketo M.M., Sugihara K.A. Randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer Res. 2003, 9:4756-4760.
10. Hull M.A., Booth J.K., Tisbury A., Scott N., Bonifer C., Markham A.F., Coletta P.L. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer 1999, 79:1399-1405.
11. Ishikawa T.O., Herschman H.R. Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis 2006, 44:143-149.
12. Ishikawa T.O., Herschman H.R. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010, 34:729-736.
13. Ishikawa T.O., Oshima M., Herschman H.R. Cox2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis 2011, 32:417-426.
14. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 2000, 60:5040-5044.
15. Jungck M., Grunhage F., Spengler U., Dernac A., Mathiak M., Caspari R., Friedl W., Sauerbruch T. E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression. Int. J. Colorectal Dis. 2004, 19:438-445.
16. Lynch P.M., Ayers G.D., Hawk E., Richmond E., Eagle C., Woloj M., Church J., Hasson H., Patterson S., Half E., Burke C.A. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am. J. Gastroenterol. 2010, 105:1437-1443.
17. Maekawa M., Sugano K., Sano H., Miyazaki S., Ushiama M., Fujita S., Gotoda T., Yokota T., Ohkura H., Kakizoe T., Sekiya T. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn. J. Clin. Oncol. 1998, 28:421-426.
18. Min/+ mice. Int. J. Cancer 2006, 119:2339-2346.
19. McCart A.E., Vickaryous N.K., Silver A. Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 2008, 204:479-490.
20. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247:322-324.
21. Naor R., Domankevich V., Shemer S., Sominsky L., Rosenne E., Levi B., Ben-Eliyahu S. Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins. Brain Behav. Immun. 2009, 23:611-621.
22. δ716 knockout mice by inhibition of cyclooxygenase 2 (COX2). Cell 1996, 87:803-809.
23. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M.M., Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta 716 mouse by rofecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2001, 61:1733-1740.
24. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., Narumiya S., Taketo M.M. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta 716) mouse intestinal polyps. Cancer Res. 2002, 62:506-511.
25. Sonoshita M., Takaku K., Oshima M., Sugihara K.I., Taketo M.M. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 2002, 62:6846-6849.
26. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B., Godio L., Patterson S., Rodriguez-Bigas M.A., Jester S.L., King K.L., Schumacher M., Abbruzzese J., DuBois R.N., Hittelman W.N., Zimmerman S., Sherman J.W., Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
27. Williams C.S., Luongo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp R.D., DuBois R.N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996, 111:1134-1140.
28. Yoo C.B., Chuang J.C., Bun H.M., Egger G., Yang A.S., Dubeau L., Long T., Laird P.W., Marquez V.E., Jones P.A. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev. Res. 2008, 1:233-240.